885520-35-4

Basic information

• Product Name: 4-BROMO-6-FLUORO (1H)INDAZOLE
• Synonyms: 4-BROMO-6-FLUOROINDAZOLE;4-BROMO-6-FLUORO (1H)INDAZOLE;1H-Indazole, 4-bromo-6-fluoro-
• CAS NO: 885520-35-4
• Molecular Formula: C₇H₄BrFN₂
• Molecular Weight: 215.02
• Mol File: 885520-35-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 331.3 °C at 760 mmHg
• Flash Point: 154.1 °C
• Appearance: /
• Density: 1.861 g/cm³
• Vapor Pressure: 0.000303mmHg at 25°C
• Refractive Index: 1.693
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.00±0.40(Predicted)
• CAS DataBase Reference: 4-BROMO-6-FLUORO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-6-FLUORO (1H)INDAZOLE(885520-35-4)
• EPA Substance Registry System: 4-BROMO-6-FLUORO (1H)INDAZOLE(885520-35-4)

Safety Data

• Hazardous Substances Data: 885520-35-4(Hazardous Substances Data)

Usage

General Description

4-Bromo-6-fluoro (1H)indazole is a chemical compound with the molecular formula C8H5BrFN2. It is a derivative of indazole, a heterocyclic aromatic organic compound. 4-BROMO-6-FLUORO (1H)INDAZOLE is primarily used as a building block in the synthesis of pharmaceuticals and agrochemicals, and also has potential applications in the field of medicinal chemistry. The presence of bromine and fluorine atoms in its structure gives it unique chemical properties, making it valuable for the development of new drugs and other functional materials. Additionally, 4-Bromo-6-fluoro (1H)indazole has found use in academic research as a reagent for the preparation of various organic compounds.

InChI:InChI=1/C7H4BrFN2/c8-6-1-4(9)2-7-5(6)3-10-11-7/h1-3H,(H,10,11)

Downstream Products

• 1425932-79-1 1-(6-fluoro-1-methyl-1H-indazol-4-yl)ethanone 
• 1056263-69-4 6-fluoro-1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazol-4-ol 
• 1056261-83-6 6-fluoro-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056263-61-6 4-bromo-6-fluoro-1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazole 

Relevant articles and documents

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.